BACKGROUND: In the HORMA (Hormonal Regulators of Muscle and Metabolism in Aging) Trial, supplemental testosterone and recombinant human growth hormone (rhGH) enhanced lean body mass, appendicular skeletal muscle mass, muscle performance, and physical function, but there was substantial interindividual variability in outcomes. METHODS:One hundred and twelve men aged 65-90 years receivedtestosterone gel (5 g/d vs 10 g/d via Leydig cell clamp) and rhGH (0 vs 3 vs 5 μg/kg/d) in a double-masked 2 × 3 factorial design for 16 weeks. Outcomes included lean tissue mass by dual energy x-ray absorptiometry, one-repetition maximum strength, Margaria stair power, and activity questionnaires. We used pathway analysis to determine the relationship between changes in hormone levels, muscle mass, strength, and function. RESULTS: Increases in total testosterone of 1046 ng/dL (95% confidence interval = 1040-1051) and 898 ng/dL (95% confidence interval = 892-904) were necessary to achieve median increases in lean body mass of 1.5 kg and appendicular skeletal muscle mass of 0.8 kg, respectively, which were required to significantly enhance one-repetition maximum strength (≥ 30%). Co-treatment with rhGH lowered the testosterone levels (quantified using liquid chromatography-tandem mass spectrometry) necessary to reach these lean mass thresholds. Changes in one-repetition maximum strength were associated with increases in stair climbing power (r = .26, p = .01). Pathway analysis supported the model that changes in testosterone and insulin-like growth factor 1 levels are related to changes in lean body mass needed to enhance muscle performance and physical function. Testosterone's effects on physical activity were mediated through a different pathway because testosterone directly affected Physical Activity Score of the Elderly. CONCLUSIONS: To enhance muscle strength and physical function, threshold improvements in lean body mass and appendicular skeletal muscle mass are necessary and these can be achieved by targeting changes in testosterone levels. rhGH augments the effects of testosterone. To maximize functional improvements, the doses of anabolic hormones should be titrated to achieve target blood levels.
RCT Entities:
BACKGROUND: In the HORMA (Hormonal Regulators of Muscle and Metabolism in Aging) Trial, supplemental testosterone and recombinant humangrowth hormone (rhGH) enhanced lean body mass, appendicular skeletal muscle mass, muscle performance, and physical function, but there was substantial interindividual variability in outcomes. METHODS: One hundred and twelve men aged 65-90 years received testosterone gel (5 g/d vs 10 g/d via Leydig cell clamp) and rhGH (0 vs 3 vs 5 μg/kg/d) in a double-masked 2 × 3 factorial design for 16 weeks. Outcomes included lean tissue mass by dual energy x-ray absorptiometry, one-repetition maximum strength, Margaria stair power, and activity questionnaires. We used pathway analysis to determine the relationship between changes in hormone levels, muscle mass, strength, and function. RESULTS: Increases in total testosterone of 1046 ng/dL (95% confidence interval = 1040-1051) and 898 ng/dL (95% confidence interval = 892-904) were necessary to achieve median increases in lean body mass of 1.5 kg and appendicular skeletal muscle mass of 0.8 kg, respectively, which were required to significantly enhance one-repetition maximum strength (≥ 30%). Co-treatment with rhGH lowered the testosterone levels (quantified using liquid chromatography-tandem mass spectrometry) necessary to reach these lean mass thresholds. Changes in one-repetition maximum strength were associated with increases in stair climbing power (r = .26, p = .01). Pathway analysis supported the model that changes in testosterone and insulin-like growth factor 1 levels are related to changes in lean body mass needed to enhance muscle performance and physical function. Testosterone's effects on physical activity were mediated through a different pathway because testosterone directly affected Physical Activity Score of the Elderly. CONCLUSIONS: To enhance muscle strength and physical function, threshold improvements in lean body mass and appendicular skeletal muscle mass are necessary and these can be achieved by targeting changes in testosterone levels. rhGH augments the effects of testosterone. To maximize functional improvements, the doses of anabolic hormones should be titrated to achieve target blood levels.
Authors: R S Swerdloff; C Wang; G Cunningham; A Dobs; A Iranmanesh; A M Matsumoto; P J Snyder; T Weber; J Longstreth; N Berman Journal: J Clin Endocrinol Metab Date: 2000-12 Impact factor: 5.958
Authors: Marc R Blackman; John D Sorkin; Thomas Münzer; Michele F Bellantoni; Jan Busby-Whitehead; Thomas E Stevens; Jocelyn Jayme; Kieran G O'Connor; Colleen Christmas; Jordan D Tobin; Kerry J Stewart; Ernest Cottrell; Carol St Clair; Katharine M Pabst; S Mitchell Harman Journal: JAMA Date: 2002-11-13 Impact factor: 56.272
Authors: Arny A Ferrando; Melinda Sheffield-Moore; Catherine W Yeckel; Charles Gilkison; Jie Jiang; Alison Achacosa; Steven A Lieberman; Kevin Tipton; Robert R Wolfe; Randall J Urban Journal: Am J Physiol Endocrinol Metab Date: 2002-03 Impact factor: 4.310
Authors: Matthew R Smith; Fred Saad; Blair Egerdie; Paul R Sieber; Teuvo L J Tammela; Chunlei Ke; Benjamin Z Leder; Carsten Goessl Journal: J Clin Oncol Date: 2012-05-29 Impact factor: 44.544
Authors: Melinda Sheffield-Moore; E Lichar Dillon; Shanon L Casperson; Charles R Gilkison; Douglas Paddon-Jones; William J Durham; James J Grady; Randall J Urban Journal: J Clin Endocrinol Metab Date: 2011-08-24 Impact factor: 5.958
Authors: E Todd Schroeder; Jiaxiu He; Kevin E Yarasheski; Ellen F Binder; Carmen Castaneda-Sceppa; Shalender Bhasin; Christina M Dieli-Conwright; Miwa Kawakubo; Ronenn Roubenoff; Stanley P Azen; Fred R Sattler Journal: Eur J Appl Physiol Date: 2011-07-12 Impact factor: 3.078
Authors: Astrid M Horstman; E Lichar Dillon; Randall J Urban; Melinda Sheffield-Moore Journal: J Gerontol A Biol Sci Med Sci Date: 2012-03-26 Impact factor: 6.053
Authors: Karyn E O'Connell; Wen Guo; Carlo Serra; Matthew Beck; Lynn Wachtman; Amber Hoggatt; Dongling Xia; Chris Pearson; Heather Knight; Micheal O'Connell; Andrew D Miller; Susan V Westmoreland; Shalender Bhasin Journal: FASEB J Date: 2014-12-02 Impact factor: 5.191
Authors: F De Stefano; S Zambon; L Giacometti; G Sergi; M C Corti; E Manzato; L Busetto Journal: J Nutr Health Aging Date: 2015-08 Impact factor: 4.075
Authors: Kerry L Hildreth; Daniel W Barry; Kerrie L Moreau; Joseph Vande Griend; Randall B Meacham; Tammie Nakamura; Pamela Wolfe; Wendy M Kohrt; J Mark Ruscin; John Kittelson; M Elaine Cress; Robert Ballard; Robert S Schwartz Journal: J Clin Endocrinol Metab Date: 2013-03-26 Impact factor: 5.958